Predicting the severity of duchenne muscular dystrophy: Implications for treatment

Neurology

Volumn 76, Issue 3, 2011, Pages 208-209

  Nelson, Stanley F ^a   Griggs, Robert C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OSTEOPONTIN;

ALLELE; CELL MIGRATION; CELL SURVIVAL; DISEASE COURSE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL;

EID: 78751637319     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182074c0e     Document Type: Editorial

References (7)

1. Moxley RT, Ashwal S, Pandya S, et al. Corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20.
2. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
3. Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997;90:717-127.
4. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002;52:832-836.
5. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011;76:219-226.
6. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009;458:1039-1042.
7. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009;119:1583-1594.